CAJ | 학술논문

目的：在前期前瞻性研究结果基础上，比较荆花胃康胶丸联合三联疗法（ helicobacter pylori， H．pylori）与铋剂四联疗法根除治疗幽门螺杆菌后患者远期消化不良症状改善和感染复发情况。方法对前期前瞻性研究中2012年9月至2013年11月于北京市5个中心就诊的H．pylori感染初治慢性胃炎患者在根除治疗H．pylori后进行为期1年的长期随访，分别对患者在停用根除治疗药物后1，6，12个月进行随访，记录患者消化不良症状，并分别于停药1，12个月后采用13 C－尿素呼气试验判断H．pylori根除和复发情况。结果共224例患者参加了研究，其中217例患者完成了1年的随访，荆花胃康组和铋剂四联组复查H．pylori 感染复发率分别为1．8％（2／113）和3．4％（2／59）。 H．pylori根除后1，6，12个月患者腹胀、嗳气、腹痛、纳差均较治疗前明显改善，差异均有统计学意义；荆花胃康组患者症状改善程度优于铋剂四联组，其中嗳气症状改善情况有统计学意义。结论荆花胃康胶丸联合三联疗法治疗H．pylori感染与铋剂四联疗法比较患者远期症状改善明显，根除治疗1年后H．pylori复发率相对较低。
목적：재전기전첨성연구결과기출상，비교형화위강효환연합삼련요법（ helicobacter pylori， H．pylori）여필제사련요법근제치료유문라간균후환자원기소화불량증상개선화감염복발정황。방법대전기전첨성연구중2012년9월지2013년11월우북경시5개중심취진적H．pylori감염초치만성위염환자재근제치료H．pylori후진행위기1년적장기수방，분별대환자재정용근제치료약물후1，6，12개월진행수방，기록환자소화불량증상，병분별우정약1，12개월후채용13 C－뇨소호기시험판단H．pylori근제화복발정황。결과공224례환자삼가료연구，기중217례환자완성료1년적수방，형화위강조화필제사련조복사H．pylori 감염복발솔분별위1．8％（2／113）화3．4％（2／59）。 H．pylori근제후1，6，12개월환자복창、애기、복통、납차균교치료전명현개선，차이균유통계학의의；형화위강조환자증상개선정도우우필제사련조，기중애기증상개선정황유통계학의의。결론형화위강효환연합삼련요법치료H．pylori감염여필제사련요법비교환자원기증상개선명현，근제치료1년후H．pylori복발솔상대교저。
Objective Based on the prospective study, this study alms to compare the effects of Jinghua Weikang capsules plus triple therapy and bismuch quadruple chemotherapy on dyspepsia symptoms and relapse of Helicobacter pylori ( H.pylori) after eradication.Methods In our previous study, patients with H.pylori infection were recruited from 5 hospitals from September 2012 to November 2013.The patients got H.pylori eradication therapies.1, 6 and 12 months after the eradication treatment, all the patients’ functional dyspepsia sympotoms were recorded and they underwent 13 C urea breath test at the 1st and 12th month respectively.Results 224 patients were enrolled in this study and 217 of them have finished the follow-up study.The relapse rate of H.pylori in Jinghua Weikang group and bismuch quadruple chemotherapy group were 1.8% (2/113) and 3.4% (2/59).The symptoms including abdominal distention, belching, stomachache and anorexia were improved significantly at 1, 6, and 12 months after the eradication of H.pylori, and the difference was significant ( P <0.001).And the improvements of Jinghua Weikang group were higher than those of bismuch quadruple chemotherapy group.There was statistical difference in the improvement of belching (P<0.05).Conclusions The symptomatic improvement of patients was better in Jinghua Weikang capsule combined with triple therapy while the relapse rate of H.pylori was relatively lower than bismuth quadruple chemotherapy.